Despite advances in treatment for multiple myeloma, the majority of patients ultimately
develop relapsed disease marked by immune evasion and resistance to standard therapy …

Chimeric antigen receptor T‐cell (CAR‐T) therapy has emerged as a highly efficacious
treatment modality for refractory and relapsed hematopoietic malignancies in recent years …

Purpose: Small cell lung cancer (SCLC) is an aggressive disease with limited treatment
options. Delta-like ligand 3 (DLL3) is highly expressed on SCLC and several other types of …

Multiple myeloma (MM) is a blood malignancy defined by an uncontrolled clonal growth of
plasma cells. Currently, new immunotherapies are being introduced that utilize BCMA to …

In multiple myeloma impressive outcomes have improved with the introduction of new
therapeutic approaches, mainly those including naked monoclonal antibodies such as …

Chimeric antigen receptor (CAR) T cells have shown promising results in the treatment of B-
cell malignancies. Despite the successes, challenges remain. One of them directly involves …

Competent T-cells with sufficient levels of fitness combat cancer formation and progression.
In multiple myeloma (MM), T-cell exhaustion is caused by several factors including tumor …

Background BCMA-directed autologous chimeric antigen receptor T (CAR-T) cells have
shown excellent clinical efficacy in relapsed or refractory multiple myeloma (RRMM) …

Multiple myeloma (MM) is a hematologic malignancy caused by the clonal expansion of
immunoglobulin-producing plasma cells in the bone marrow and/or extramedullary sites …

Despite the remarkable success of autologous chimeric antigen receptor (CAR) T cells,
some patients relapse due to tumor antigen escape and low or uneven antigen expression …